eMedicine Specialties > Physical Medicine and Rehabilitation > Medical Diseases
Osteoporosis (Secondary): Multimedia
Updated: Jun 25, 2009
Multimedia
 | Media file 1: Osteoporosis of the spine. Observe the considerable reduction in overall vertebral bone density and note the lateral wedge fracture of L2. |
 | Media file 2: Osteoporosis of the spine. Note the lateral wedge fracture in L3 and the central burst fracture in L5. The patient had suffered a recent fall. |
 | Media file 3: Normal femoral anatomy. |
 | Media file 4: Stable intertrochanteric fracture of the femur. |
 | Media file 5: Percutaneous vertebroplasty, transpedicular approach. |
 | Media file 6: In kyphoplasty, a KyphX inflatable bone tamp is percutaneously advanced into the collapsed vertebral body (A). It is then inflated, (B) elevating the depressed endplate, creating a central cavity, and compacting the remaining trabeculae to the periphery. Once the balloon tamp is deflated and withdrawn, the cavity (C) is filled under low pressure with a viscous preparation of methylmethacrylate (D). |
 | Media file 7: Reduction in kyphotic angulation after kyphoplasty. |
More on Osteoporosis (Secondary) |
| Overview: Osteoporosis (Secondary) |
| Differential Diagnoses & Workup: Osteoporosis (Secondary) |
| Treatment & Medication: Osteoporosis (Secondary) |
| Follow-up: Osteoporosis (Secondary) |
 Multimedia: Osteoporosis (Secondary) |
| References |
| Further Reading |
| « Previous Page |
References
Ahmed SF, Elmantaser M. Secondary osteoporosis. Endocr Dev. 2009;16:170-190. [Medline].
[Best Evidence] Majumdar SR, Lier DA, Beaupre LA, et al. Osteoporosis case manager for patients with hip fractures: results of a cost-effectiveness analysis conducted alongside a randomized trial. Arch Intern Med. Jan 12 2009;169(1):25-31. [Medline].
Rosen CJ, Tenenhouse A. Biochemical markers of bone turnover. A look at laboratory tests that reflect bone status. Postgrad Med. Oct 1998;104(4):101-2, 107-10, 113-4.
Melton LJ 3rd, Sampson JM, Morrey BF, Ilstrup DM. Epidemiologic features of pelvic fractures. Clin Orthop Relat Res. Mar-Apr 1981;43-7. [Medline].
Migliaccio S, Brama M, Malavolta N. Management of glucocorticoids-induced osteoporosis: role of teriparatide. Ther Clin Risk Manag. Apr 2009;5(2):305-10. [Medline]. [Full Text].
Jensen GF, Christiansen C, Boesen J, et al. Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. Clin Orthop. Jun 1982;(166):75-81. [Medline].
Melton LJ 3d, Kan SH, Frye MA, et al. Epidemiology of vertebral fractures in women. Am J Epidemiol. May 1989;129(5):1000-11. [Medline].
Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med. Mar 23 1995;332(12):767-73. [Medline]. [Full Text].
Mann GB, Kang YC, Brand C, et al. Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance. J Clin Oncol. Jun 22 2009;[Medline].
Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. Oct 2002;87(10):4431-7.
Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science. Jul 3 1992;257(5066):88-91. [Medline].
[Best Evidence] Kastner M, Straus SE. Clinical decision support tools for osteoporosis disease management: a systematic review of randomized controlled trials. J Gen Intern Med. Dec 2008;23(12):2095-105. [Medline].
Sinaki M, Mikkelsen BA. Postmenopausal spinal osteoporosis: flexion versus extension exercises. Arch Phys Med Rehabil. Oct 1984;65(10):593-6. [Medline].
Jensen ME, Evans AJ, Mathis JM, et al. Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects. AJNR Am J Neuroradiol. Nov-Dec 1997;18(10):1897-904. [Medline]. [Full Text].
National Osteoporosis Foundation. Executive Summary of Osteoporosis. Washington, DC: Osteoporosis International;1998.
National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington, DC;1998.
Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med. Feb 19 1998;338(8):485-92. [Medline]. [Full Text].
Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. Mar 2005;90(3):1294-301.
Body JJ, Gaich GA, Scheele WH, et al. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. Oct 2002;87(10):4528-35.
Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. Oct 2001;16(10):1846-53.
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. May 10 2001;344(19):1434-41. [Medline]. [Full Text].
Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int. Dec 2004;15(12):992-7.
Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. Sep 25 2003;349(13):1216-26. [Medline]. [Full Text].
Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. Aug 11 2005;353(6):566-75. [Medline]. [Full Text].
Deal C, Omizo M, Schwartz EN, et al. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. Nov 2005;20(11):1905-11. [Medline].
Ste-Marie LG, Schwartz SL, Hossain A, et al. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy. J Bone Miner Res. Feb 2006;21(2):283-91. [Medline].
American Journal of Medicine. Consensus Development Conference on Osteoporosis. Hong Kong, April 1-2, 1993. Am J Med. Nov 30 1993;95(5A):1S-78S. [Medline].
American Journal of Medicine. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. Jun 1993;94(6):646-50. [Medline].
Baillie SP, Davison CE, Johnson FJ, Francis RM. Pathogenesis of vertebral crush fractures in men. Age Ageing. Mar 1992;21(2):139-41.
Blake GM, Fogelman I. Long-term effect of strontium ranelate treatment on BMD. J Bone Miner Res. Nov 2005;20(11):1901-4. [Medline].
Blake JM, Collins JA, Reid RL, et al. The SOGC statement on the WHI report on estrogen and progestin use in postmenopausal women. J Obstet Gynaecol Can. Oct 2002;24(10):783-90, 793-802.
Boden SD. Diagnostic imaging of the spine. In: Weinstein JN, Rydevik BL, Sonntag VKH, eds. Essentials of the Spine. New York: Raven Press;1995: 97-110.
Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. Feb 15 2006;12(4):1221-8. [Medline].
Bostrom MP, Lane JM. Future directions. Augmentation of osteoporotic vertebral bodies [published erratum appears in Spine 1998 Sep 1;23(17):1922]. Spine. Dec 15 1997;22(24 Suppl):38S-42S. [Medline].
Bronk J, Urabe K, Liang T, et al. The effects of age on fracture repair in a rat femur model. Trans Orthop Res Soc. 1996;42:200.
Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. Nov 12 2002;167(10 Suppl):S1-34.
Bruni V, Dei M, Filicetti MF, et al. Predictors of bone loss in young women with restrictive eating disorders. Pediatr Endocrinol Rev. Jan 2006;3 Suppl 1:219-21.
Burlet N, Reginster JY. Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis. Clin Orthop Relat Res. Feb 2006;443:55-60.
Campistol JM, Holt DW, Epstein S, et al. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int. Sep 2005;18(9):1028-35.
Caplan GA, Scane AC, Francis RM. Pathogenesis of vertebral crush fractures in women. J R Soc Med. Apr 1994;87(4):200-2.
Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. Dec 3 1992;327(23):1637-42. [Medline].
Cole A, Herzog R. The lumbar spine: Imaging options. In: Cole A, Herring S, eds. The Low Back Pain Handbook. Philadelphia, PA: Hanley and Belfus, Inc;1997; 179-81.
Cybulski GR. Methods of surgical stabilization for metastatic disease of the spine. Neurosurgery. Aug 1989;25(2):240-52. [Medline].
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. Sep 4 1997;337(10):670-6. [Medline].
Delmas PD. Biochemical markers of bone turnover. J Bone Miner Res. Dec 1993;8 Suppl 2:S549-55. [Medline].
Delmas PD. Hormone replacement therapy in the prevention and treatment of osteoporosis. Osteoporos Int. 1997;7 Suppl 1:S3-7. [Medline].
Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. Dec 4 1997;337(23):1641-7. [Medline].
Deramond H, Depriester C, Galibert P, Le Gars D. Percutaneous vertebroplasty with polymethylmethacrylate. Technique, indications, and results. Radiol Clin North Am. May 1998;36(3):533-46. [Medline].
Eastell R. Assessment of bone density and bone loss. Osteoporosis Int. 1996;6 Suppl 2:S3-5.
Favur MJ. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 3rd ed. Philadelphia, Pa: Lippincott-Raven;116, 249.
Francis RM, Peacock M, Marshall DH, et al. Spinal osteoporosis in men. Bone Miner. Mar 1989;5(3):347-57.
Frye MA, Melton LJ 3d, Bryant SC, et al. Osteoporosis and calcification of the aorta. Bone Miner. Nov 1992;19(2):185-94. [Medline].
Gangi A, Kastler BA, Dietemann JL. Percutaneous vertebroplasty guided by a combination of CT and fluoroscopy. AJNR Am J Neuroradiol. Jan 1994;15(1):83-6. [Medline].
Haden ST, Fuleihan GE, Angell JE, et al. Calcidiol and PTH levels in women attending an osteoporosis program. Calcif Tissue Int. Apr 1999;64(4):275-9. [Medline].
Hassager C, Fabbri-Mabelli G, Christiansen C. The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen. Osteoporos Int. Jan 1993;3(1):50-2. [Medline].
Heaney RP, Avioli LV, Chestnut C, et al. Is bone the cause of osteoporotic fracture or its consequence?. J Bone Miner Res. 1988;3:79S.
Jackson JA, Kleerekoper M. Osteoporosis in men: diagnosis, pathophysiology, and prevention. Medicine (Baltimore). May 1990;69(3):137-52. [Medline].
Johnson BE, Lucasey B, Robinson RG, Lukert BP. Contributing diagnoses in osteoporosis. The value of a complete medical evaluation. Arch Intern Med. May 1989;149(5):1069-72.
Kanis J, Johnell O, Gullberg B, et al. Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporos Int. 1999;9(1):45-54.
Kanis JA, Melton LJ 3rd, Christiansen C. The diagnosis of osteoporosis. J Bone Miner Res. Aug 1994;9(8):1137-41. [Medline].
Kelepouris N, Harper KD, Gannon F, et al. Severe osteoporosis in men. Ann Intern Med. Sep 15 1995;123(6):452-60.
Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol. Dec 2005;19(6):1021-37. [Medline].
Kimble RB, Vannice JL, Bloedow DC, et al. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest. May 1994;93(5):1959-67. [Medline].
LaCroix AZ. Estrogen with and without progestin: benefits and risks of short-term use. Am J Med. Dec 19 2005;118(12 Suppl 2):79-87.
Lee N, Radford-Smith G, Taaffe DR. Bone loss in Crohn's disease: exercise as a potential countermeasure. Inflamm Bowel Dis. Dec 2005;11(12):1108-18. [Medline].
Lee WY, Oh KW, Rhee EJ, et al. Relationship between subclinical thyroid dysfunction and femoral neck bone mineral density in women. Arch Med Res. May 2006;37(4):511-6. [Medline].
Lieberman IH, Dudeney S, Reinhardt MK, Bell G. Initial outcome and efficacy of "kyphoplasty" in the treatment of painful osteoporotic vertebral compression fractures. Spine. Jul 15 2001;26(14):1631-8.
Lindsay R. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis Int. 1998;8 Suppl 4:S1-S88.
Majumbar S. QMR in assessment of trabecular bone mineral density and structure. Presented at: 4th International Symposium on Osteoporosis;March 1993.
Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. Feb 2 1995;332(5):305-11. [Medline].
Marie PJ. Strontium as therapy for osteoporosis. Curr Opin Pharmacol. Dec 2005;5(6):633-6.
McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. Feb 23 2006;354(8):821-31.
Melton LJ, Crowson CS, Khosla S, O''Fallon WM. Fracture risk after surgery for peptic ulcer disease: a population-based cohort study. Bone. Jul 1999;25(1):61-7.
Melton LJ, Riggs BL. The Osteoporotic Syndrome: Detection, Prevention, and Treatment. New York: Grune and Stratton;1983: 45-72.
Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. May 1982;34(3):285-90. [Medline].
Naessen T, Persson I, Adami HO, et al. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med. Jul 15 1990;113(2):95-103. [Medline].
National Osteoporosis Foundation. Understanding Osteoporosis: A Survey of American Women. Gallup Survey. Washington, DC;1991.
Neer RM. Osteoporosis. In: DeGroot LJ, ed. Endocrinology. Philadelphia, Pa: WB Saunders; 1994:. 1228-58.
Nicola N, Lins E. Vertebral hemangioma: retrograde embolization-stabilization with methyl methacrylate. Surg Neurol. May 1987;27(5):481-6. [Medline].
Okinaga H, Matsuno A, Okazaki R. High risk of osteopenia and bone derangement in postsurgical patients with craniopharyngiomas, pituitary adenomas and other parasellar lesions. Endocr J. Dec 2005;52(6):751-6.
Panigrahi K, Delmas PD, Singer F, et al. Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. Clin Chem. May 1994;40(5):822-8. [Medline].
Parfitt AM. Morphologic basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis. Miner Electrolyte Metab. 1980;4:273-87.
Parfitt AM. Trabecular bone architecture in the pathogenesis and prevention of fracture. Am J Med. Jan 26 1987;82(1B):68-72. [Medline].
Parfitt AM, Mundy GR, Roodman GD, et al. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. Feb 1996;11(2):150-9. [Medline].
Peris P, Guañabens N, Monegal A, et al. Aetiology and presenting symptoms in male osteoporosis. Br J Rheumatol. Oct 1995;34(10):936-41.
Poór G, Atkinson EJ, O''Fallon WM, Melton LJ 3rd. Predictors of hip fractures in elderly men. J Bone Miner Res. Dec 1995;10(12):1900-7.
Prescrire International. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns. Prescrire Int. Dec 2005;14(80):207-11.
Price PA, Parthemore JG, Deftos LJ. New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest. Nov 1980;66(5):878-83. [Medline].
Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. May 2005;90(5):2816-22.
Rupp RE, Ebraheim NA, Coombs RJ. Magnetic resonance imaging differentiation of compression spine fractures or vertebral lesions caused by osteoporosis or tumor. Spine. Dec 1 1995;20(23):2499-503; discussion 2504. [Medline].
Seeman E, Melton LJ, O''Fallon WM, Riggs BL. Risk factors for spinal osteoporosis in men. Am J Med. Dec 1983;75(6):977-83.
Segrest JP, Cunningham LW. Variations in human urinary O-hydroxylysyl glycoside levels and their relationship to collagen metabolism. J Clin Invest. Aug 1970;49(8):1497-509. [Medline].
Siddall PJ, Cousins MJ. Spinal pain mechanisms. Spine. Jan 1 1997;22(1):98-104.
Solomon L. Osteoporosis and fracture of the femoral neck in the South African Bantu. J Bone Joint Surg [Br]. Feb 1968;50(1):2-13. [Medline].
Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin North Am. Mar 2003;32(1):115-34, vii.
Steinmann J, Tingey CT, Cruz G, Dai Q. Biomechanical comparison of unipedicular versus bipedicular kyphoplasty. Spine. Jan 15 2005;30(2):201-5.
Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med. Feb 6 1992;326(6):357-62.
Wasnich R. Bone mass measurement: prediction of risk. Am J Med. Nov 30 1993;95(5A):6S-10S.
White AH, Derby R, Wynne G. Epidural injections for the diagnosis and treatment of low-back pain. Spine. Jan-Feb 1980;5(1):78-86. [Medline].
Yasuda Y, Kaleta J, Brömme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev. May 25 2005;57(7):973-93.
Yaturu S, DjeDjos S, Alferos G, Deprisco C. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy. Prostate Cancer Prostatic Dis. 2006;9(1):35-8.
Further Reading
Related eMedicine topics:
Fracture, Femur
Histology of Bone
Intertrochanteric Hip Fractures
Lumbar Compression Fracture
Nonoperative Treatment of Osteoporotic Compression Fractures
Osteoporosis [Orthopedic Surgery]
Osteoporosis [Pediatrics: General Medicine]
Osteoporosis and Spinal Cord Injury
Osteoporosis in Solid Organ Transplantation
Osteoporosis (Primary)
Utility of Bone Markers in Osteoporosis
Vertebral Fracture
Clinical guidelines:
ACR Appropriateness Criteria® osteoporosis and bone mineral density. American College of Radiology - Medical Specialty Society. 1998 (revised 2007). 12 pages. NGC:005990
Diagnosis and treatment of osteoporosis. Institute for Clinical Systems Improvement - Private Nonprofit Organization. 2002 Aug (revised 2008 Sep). 67 pages. NGC:006738
Clinical trials:
Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects
Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients
Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-Induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
Keywords
secondary osteoporosis, osteoporosis, bone density, bone loss, bone disease, hip fracture, Forteo, alendronate, bisphosphonate, osteoporosis treatment, osteoporosis exercise, bone mass, bone densitometry, bone mineral density, broken hip, hip fractures, teriparatide, metabolic bone disease, vertebral compression fracture
